Dear Colleagues,

NCI plans to launch a national, longitudinal, natural history study of COVID-19 in people with cancer in mid May 2020. The study, named NCI COVID-19 in Cancer Patients Study (N-CCaPS), will be open to adults who are undergoing a test for SARS-CoV-2 or already have COVID-19 and are undergoing cancer treatment that requires them to go to a health care facility for chemotherapy, targeted therapy, immunotherapy, and/or radiation therapy. The trial plans to expand to include children with cancer and COVID-19 after the launch.

We hope to enroll patients at more than 1,000 sites across the United States and encourage your site to participate in this important study.

The study will:

- Help scientists better understand the natural history of COVID-19 in people with cancer
- Collect comprehensive longitudinal data, imaging scans and serial blood specimens
- Build a clinical database and repository of blood samples and imaging scans
- Investigate how cancer treatment and cancer outcomes are affected by COVID-19
- Identify clinical and molecular factors associated with severe COVID-19 and mortality
- Assess long-term effects of COVID-19 on cancer outcomes and quality of life

We understand that many institutions have already launched locally-based cancer and COVID-19 studies and may already be participating in de-identified registries; this study will complement those ongoing efforts. N-CCaPS will be available to all National Clinical Trials Network (NCTN), NCI Community Oncology Research Group (NCORP) and NCI Experimental Therapeutics Clinical Trials Network (ETCTN) sites via the Cancer Trials Support Unit (CTSU). Please note NCI will provide per-case accrual reimbursement to participating sites.

Once the study activates, it will be available on the CTSU website. In the interim, we want to ensure that you are aware of this coordinated NCI effort.

If you wish to receive automatic notifications of study updates, please sign up here.

We hope that the information learned from this study may help guide future treatment for cancer patients that develop COVID-19 and improve patient outcomes.

Sincerely,

James H. Doroshow, M.D.
Deputy Director for Clinical and Translational Research
National Cancer Institute, NIH
Building 31, Room 3A44
31 Center Drive
Bethesda, MD 20892
240-781-3320
doroshoj@mail.nih.gov